Logo

Using Patient Specific iPSC-Cardiomyocytes for Disease Modeling

Ulrich Broeckel, MD
Tuesday, March 31, 2015
Tweet
Transcript Embed
  • Email
  • Bookmark
  • <<
  • <
  • >
  • >>

Tweet
Facebook
  • Email

Chapters

  • Introduction
  • Conflict of Interest
  • CONGRATULATIONS!
  • Generate data; Interpret data? Implement data?
  • Questions
  • Translational Precision Medicine
  • Next Steps Concept
  • Left Ventricular Hypertrophy
  • Study Population
  • iPS Derivation Status
  • CM Quality Parameters
  • Human Cardiomyocyte Model of Hypertrophy
  • HT Assay Platform
  • Protocol Development
  • First Round of Production Phenotyping: African American
  • miRNA and Cardiovascular Disease
  • miRNA Sequence Analysis
  • Knock Down: Predicted miRNAs
  • Knock Down: Expression Analysis
  • Variation Between Lines
  • Variation between iPSC-CM Lines
  • Develop Drug Screening Assay
  • Primary Screen at 5μM Hits >50% activity compared with Macitentan control
  • Develop Drug Screening Assay
  • Summary
  • Acknowledgement
 

No transcript for this webinar

More InformationRequest info